Episode notes
Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.
Podcast
Talking Points
TCTMD · Tech & Science · English
A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b
More from Talking Points All episodes →
-
14 Oct 2026 · 6 minNew
The BHF PROTECT-TAVI Trial
Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.
-
16 Sep 2026 · 9 min
The FAME 3 Trial
William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.
-
2 Sep 2026 · 8 min
The TRILUMINATE Pivotal Trial
Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.
-
22 Jul 2026 · 9 min
The BETAMI-DANBLOCK Trial
How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
-
1 Jul 2026 · 1 hr 33 min
New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI
In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.
-
3 Jun 2026 · 9 min
The PROCTOR Trial
Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.
-
20 May 2026 · 5 min
The SELUTION DeNovo Trial
Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.
-
6 May 2026 · 7 min
The VESALIUS-CV Trial
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.
